A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double Blind, Placebo Controlled, Parallel Group Study, Including an Open-Label Period, Evaluating the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab for the Treatment of Posttraumatic Headache (PTH)
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Fremanezumab (Primary)
- Indications Post-traumatic headache
- Focus Proof of concept; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 10 Jun 2019 Planned End Date changed from 20 Oct 2020 to 13 Jan 2021.
- 10 Jun 2019 Planned primary completion date changed from 20 Oct 2020 to 21 Oct 2020.
- 24 Apr 2019 Planned End Date changed from 11 Dec 2019 to 20 Oct 2020.